Ethris

Executive Summary

Ethris GmbH is a German biotechnology company pioneering mRNA-based therapeutics and vaccines for respiratory diseases. Founded in 2009 and headquartered in Munich, the company leverages its proprietary non-immunogenic mRNA and lipid nanoparticle (LNP) delivery platform to enable targeted delivery to the respiratory tract, addressing conditions with high unmet medical need. Ethris's platform aims to overcome key challenges in mRNA therapeutics, including immunogenicity and stability, by designing mRNA constructs that avoid innate immune activation and using LNPs optimized for pulmonary delivery. The company's lead programs focus on inhaled mRNA vaccines and therapies for respiratory infections and chronic lung diseases, such as RSV, influenza, and potentially cystic fibrosis or asthma. Ethris differentiates itself through its unique mRNA chemistry and delivery technology, which may enable repeat dosing and improved safety profiles. While the company remains in a relatively early stage compared to mRNA giants like Moderna and BioNTech, its specialized approach to respiratory applications and its strong intellectual property portfolio position it as a potential player in the growing mRNA therapeutics space. Ethris has not disclosed significant funding rounds or partnerships, but its technology has attracted interest from academic and industry collaborators. The company's progress in preclinical and clinical studies will be critical to validating its platform and advancing toward commercialization.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for inhaled mRNA vaccine candidate (e.g., RSV or influenza)35% success
• Q2 2027Partnership or licensing deal with a major pharmaceutical company for respiratory mRNA platform40% success
• Q3 2026Series B or C financing round to support clinical development50% success